Cystic Fibrosis: The Brussels University Hospital, a Leading Reference Center in the Fight Against the Disease

As part of European Cystic Fibrosis Week, taking place from November 18 to 24, 2024, the  Brussels University Hospital (H.U.B.), a recognized reference institution in this field, highlights the severity and challenges posed by this still-incurable genetic disease

Image
kid_muco.jpg

A Disease That Overwhelms Body and Life

Also known as cystic fibrosis, this hereditary condition profoundly impacts the body. For young patients, it is a daily battle against excessively thick mucus that clogs the lungs, obstructs airways, fosters infections, and gradually impairs respiratory function.

As if this weren’t enough, patients also face difficulties in absorbing fats, a relentless side effect that heavily burdens their overall health. For those affected, cystic fibrosis demands constant medical attention and an ongoing effort to maintain an acceptable quality of life despite these challenges.

Ce dispositif unique en Belgique permet aux patients de bénéficier d’une continuité des soins tout au long de leur vie

Pr Hanssens et Pr Knoop

A Multidisciplinary Approach for Personalized Care

At HUDERF, the care pathway is supported by a multidisciplinary team composed of doctors, nurses, dieticians, physiotherapists, social workers, psychologists, administrative staff, and pharmacists. This close coordination aims to optimize consultation times and minimize the risk of infections.

Upon arrival, patients are placed in a dedicated room where specialists take turns providing their care. This well-organized approach ensures that treatment is tailored to the specific needs of this demanding condition, which requires daily and intensive management.

A Major Breakthrough with Protein Therapy

Since 2022, a protein therapy developed with contributions from H.U.B. teams has transformed the outlook for many patients with cystic fibrosis. By targeting the genetic causes of the disease, this treatment significantly improves the quality of life for over 85% of affected patients, offering them the hope of a life closer to normal and an extended life expectancy. This is a groundbreaking milestone in the fight against cystic fibrosis.

Hope for Gene Therapy Developments

However, protein therapy does not benefit all patients. For the 10 to 15% who cannot access this treatment, the H.U.B. is actively researching alternatives such as phage therapy and exploring advances in gene therapy. Although still experimental, this approach offers hope for a potential cure by directly targeting the genetic mutations responsible for cystic fibrosis.

Through its commitment, the Université Hospital of Brussels provides patients with the opportunity to grow up with greater peace of mind and ultimately aims to help them achieve more autonomy in managing their condition.